Vascular Smooth Muscle Cell Genomics in Arterial Remodeling

Abstract

Arterial remodeling is a complex process influenced by the dynamic behavior of vascular smooth muscle cells (VSMCs). Recent genomic investigations have elucidated the molecular underpinnings of VSMC phenotypic modulation, revealing novel pathogenic mechanisms in vascular diseases. This review synthesizes current scientific evidence on VSMC genomics and its clinical relevance in arterial remodeling, integrating epidemiological data, mechanistic insights, risk stratification, diagnostic advances, therapeutic interventions, emerging therapies, and contemporary guideline recommendations. The article aims to provide clinicians and researchers with a comprehensive understanding of the implications of VSMC genomics in the management of arterial diseases.

Introduction

Vascular smooth muscle cells (VSMCs) play a pivotal role in maintaining vascular integrity, regulating blood flow, and contributing to the pathophysiology of arterial remodeling. Arterial remodeling, defined as structural and functional changes in the vessel wall in response to hemodynamic stimuli or injury, is central to the development and progression of atherosclerosis, hypertension, restenosis, and aneurysms. Over the past decade, advances in genomics have transformed our understanding of VSMC biology, uncovering genetic and epigenetic factors that govern cellular phenotypic plasticity, proliferation, migration, and extracellular matrix remodeling. This article provides a detailed review of the genomic determinants of VSMC function, their implications in arterial remodeling, and the translation of these findings into clinical practice.

Epidemiology / Disease Burden

Arterial remodeling is a hallmark of several prevalent cardiovascular diseases, including atherosclerosis, peripheral artery disease, and hypertension. Globally, cardiovascular disease remains the leading cause of morbidity and mortality, with an estimated 18 million deaths annually. The burden of arterial remodeling-related complications is particularly high in aging populations and individuals with metabolic syndrome. Genetic predispositions affecting VSMC function have been identified in familial forms of arterial diseases, underscoring the significance of genomic research in elucidating population-specific risks and informing public health strategies.

Pathophysiology

The pathophysiology of arterial remodeling is intricately linked to VSMC phenotypic modulation, wherein contractile VSMCs transition to a synthetic, proliferative, and migratory phenotype. Genomic studies have revealed that mutations and polymorphisms in genes encoding key transcription factors (e.g., KLF4, myocardin), contractile proteins (e.g., ACTA2, MYH11), and signaling molecules (e.g., TGF-β, Notch, PDGF pathways) drive this phenotypic switch. Epigenetic modifications, including DNA methylation, histone acetylation, and non-coding RNAs, further regulate gene expression patterns within VSMCs. Single-cell RNA sequencing has uncovered previously unrecognized VSMC subpopulations with distinct genomic signatures contributing to diverse remodeling responses, such as neointima formation, calcification, or fibrous cap stability. These discoveries have provided mechanistic explanations for the heterogeneity observed in clinical arterial remodeling phenotypes.

Risk Factors

Both genetic and environmental factors modulate the risk of pathological arterial remodeling mediated by VSMCs. Heritable mutations in VSMC-related genes (e.g., ACTA2, MYH11) confer a heightened risk for familial thoracic aortic aneurysms and dissections. Common genetic variants identified through genome-wide association studies (GWAS) influence susceptibility to atherosclerosis, hypertension, and restenosis. Environmental factors such as hypertension, hyperglycemia, dyslipidemia, and smoking interact with the genomic landscape, exacerbating VSMC dysfunction and maladaptive remodeling. Understanding the interplay between inherited and acquired risk factors is essential for identifying high-risk individuals and tailoring precision medicine approaches.

Clinical Features

The clinical manifestations of arterial remodeling are diverse, ranging from asymptomatic arterial wall thickening to symptomatic stenosis, aneurysm formation, or vessel rupture. VSMC-driven remodeling contributes to luminal narrowing in atherosclerosis, vascular stiffening in hypertension, and wall weakening in aneurysms. Patients may present with ischemic symptoms, pulse deficits, or acute vascular events such as myocardial infarction or stroke. Familial forms of arterial diseases often present at a younger age and may be associated with syndromic features resulting from germline mutations in VSMC-related genes.

Diagnosis

Diagnosis of pathological arterial remodeling involves a combination of clinical assessment, imaging modalities, and, increasingly, genetic testing. Non-invasive imaging techniques, such as carotid and femoral ultrasound, CT angiography, and MRI, allow for detailed assessment of arterial wall structure, lumen size, and plaque characteristics. In patients with suspected familial vascular diseases, targeted genetic testing for known VSMC-related gene mutations is recommended. Emerging molecular biomarkers, including circulating microRNAs and cell-free DNA, offer promise for early detection and risk stratification based on VSMC genomic activity.

Treatment & Management

Current management strategies for arterial remodeling focus on controlling modifiable risk factors (e.g., hypertension, dyslipidemia, diabetes), antiplatelet and lipid-lowering therapies, and surgical or endovascular interventions for advanced disease. While these approaches target the downstream effects of remodeling, emerging strategies aim to directly modulate VSMC behavior. Pharmacological agents targeting growth factor signaling, inflammatory pathways, and VSMC phenotypic modulation are under investigation. In familial cases, genetic counseling and cascade screening are integral to management. Multidisciplinary care involving cardiology, vascular surgery, and genetic specialists is recommended for complex cases.

Recent Advances / Emerging Therapies

Recent advances in VSMC genomics have catalyzed the development of novel therapeutic approaches. CRISPR/Cas9-mediated gene editing, antisense oligonucleotides, and small-molecule modulators of epigenetic regulators hold potential for correcting pathogenic VSMC phenotypes. Preclinical studies have demonstrated promising results with agents targeting microRNA networks (e.g., miR-145, miR-21) and transcriptional modulators (e.g., KLF4 inhibitors) to attenuate neointimal hyperplasia and stabilize atherosclerotic plaques. Personalized medicine approaches leveraging patient-specific genomic profiles are being explored to optimize therapy selection and improve clinical outcomes. Ongoing clinical trials are evaluating the safety and efficacy of these novel interventions in high-risk patient populations.

Guideline Recommendations

Contemporary clinical guidelines emphasize the importance of comprehensive risk assessment, early identification of familial vascular disease, and aggressive management of modifiable risk factors in patients with evidence of arterial remodeling. Genetic testing is recommended for individuals with early-onset arterial disease, suggestive family history, or syndromic features. Multimodal imaging and regular surveillance are advised for patients with known VSMC gene mutations. As emerging therapies advance toward clinical application, guideline committees are expected to integrate genomic information into risk stratification and management algorithms, fostering individualized care pathways.

Conclusion

The integration of VSMC genomics into the clinical paradigm of arterial remodeling represents a major advance in vascular medicine. Genomic insights have elucidated the molecular mechanisms underlying VSMC-driven remodeling, enabled precision risk assessment, and informed the development of targeted therapies. Continued translational research and collaboration between clinicians, geneticists, and basic scientists are essential to realize the full potential of VSMC genomics in improving outcomes for patients with arterial diseases.